Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.35 |
| ▸ | CDK2 | P24941 | 10/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028223 | 0.80 | CDK2 (0.33) | KCNH2CDK2MAPK1ATMCCNT1 | |
| SCHEMBL1713226 | 0.79 | ALDH1A1 (0.46) | MAPK1 | |
| SCHEMBL3625293 | 0.77 | ALOX15 (0.38) | — | |
| SCHEMBL14477882 | 0.77 | POLB (0.32) | POLBHTT | |
| SCHEMBL278962 | 0.74 | MAPT (0.40) | SMN1; SMN2POLBHTT | |
| SCHEMBL1447556 | 0.74 | CDK2 (0.40) | CDK2 | |
| SCHEMBL1204351 | 0.74 | ALDH1A1 (0.36) | MAPK1ATMSMN1; SMN2POLBHTT | |
| SCHEMBL5102686 | 0.73 | CDK2 (0.42) | CDK2ATMHTT | |
| SCHEMBL3552233 | 0.72 | CDK2 (0.33) | KCNH2CDK2 | |
| SCHEMBL3552240 | 0.72 | CDK2 (0.33) | KCNH2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4573094-A2 | CDK2 INHIBITORS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1927590-B1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20090306399-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-2044058-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| EP-1927590-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007148070-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148070-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
| EP-1869016-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006095159-A1 | (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | WO | disclosed |
| CN-1269813-C | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | KCNH2 4185/4885CDK2 23/4885MAPK1 1335/4885 |
| US-20090306399-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | AADAC, KAT5, HDAC5 | KCNH2 311/4885CDK2 1765/4885MAPK1 2046/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | KCNH2 4836/4885CDK2 1/4885MAPK1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.